Low-molecular-weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis;Heparinas de bajo peso molecular frente a heparinas no fraccionadas en el tratamiento de la trombosis venosa profunda

Anales de Medicina Interna

Volumn 18, Issue 7, 2001, Pages 364-368

  Moreno Palomares, J J ^a   Fisac Herrero, R M ^a   Herrero Domingo, A ^a   Ferreira Pasos, E M ^a   Grasa, J ^a   Reverte Cejudo, D ^a  

^a HOSPITAL GENERAL DE SEGOVIA   (Spain)

Author keywords

Law molecular weight heparin; Thromboembolic disease; Treatment

Indexed keywords

DALTEPARIN; DICOUMAROL; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ANTICOAGULANTS; DALTEPARIN; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; VENOUS THROMBOSIS;

EID: 0034904667     PISSN: 02127199     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Starting prophylaxis for venous thromboembolism postoperatively
2. Consensus Conference on antithrombotic therapy
3. Prevención de la enfermedad tromboembólica venosa: Heparinas no fraccionadas y heparinas de bajo peso molecular. Análisis de estas dos opciones
4. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis
5. A Collaborative European Multicentre Study. A randomized trial of subcutaneous low-molecular-weight heparin compared with intravenous unfractionated heparin in the treatment of deep-vein thrombosis
6. Comparison of once-daily subcutaneous Fragmin, with continuous intravenous unfractionated heparin in the treatment of deep-vein thrombosis
7. Subcutaneous low-molecular-weight heparin compared with continuos intravenous heparin in the treatment of proximal vein thrombosis
8. Treatment of deep venous thrombosis and pulmonary embolism. Current recommendations
9. International consensus recommendations: Summary statement and additional suggested guidelines
10. Management of venous thromboembolism
11. Unfractionated and low-molecular-weight heparin in the treatment of venous thromboembolic disease
12. Use of low-molecular-weight heparin in the treatment of venous thromboembolic disease. Answer to frequently asked questions
13. A comparison of subcutaneous low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism
14. Once daily subcutaneous dalteparin for the initial treatment of acute deep vein thrombosis
15. Low-dose low-molecular-weight heparin is anti-inflammatory during venous thrombosis
16. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis
17. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home
18. Assessment of outpatient treatment of deep-vein thrombosis with low-molecular-weight heparin
19. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight heparin: A comparison of patient self-injection with homecare injection
20. Replacing inpatient care by outpatient care in the treatment of deep venous thrombosis: An economic evaluation
21. Treatment of proximal vein thrombosis with subcutaneous low-molecular-weigh heparin versus intravenous heparin. An economic perspective
22. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine,) compared with intravenous heparin in the curative treatment of submasive pulmonary embolism: A dose-ransing study
23. Subcutaneous low-molecular-weight heparin Fragmin, versus intravenous unfractionated heparin in the treatment of acute non-massive pulmonary embolism: An open randomized pilot study
24. Low molecular heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia
25. Low-molecular-weight heparins and unstable angina. Current perspectives
26. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin
27. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolis
28. Testing for occult cancer in patients with idiopathic deep vein thrombosis. A decision analysis
29. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism
30. Clinical uses of low-molecular-weight heparins